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The Notch pathway is a well-established mediator of cell–cell communication that plays a
critical role in stem cell survival, self-renewal, cell fate decisions, tumorigenesis, invasion,
metastasis, and drug resistance in a variety of cancers. An interesting form of crosstalk
exists between the Notch receptor and the Epidermal Growth Factor Receptor Tyrosine
Kinase family, which consists of HER-1, -2, -3, and -4. Overexpression of HER and/or
Notch occurs in several human cancers including brain, lung, breast, ovary, and skin making
them potent oncogenes capable of advancing malignant disease. Continued assessment
of interplay between these two critical signaling networks uncovers new insight into mech-
anisms used by HER-driven cancer cells to exploit Notch as a compensatory pathway. The
compensatory Notch pathway maintains HER-induced downstream signals transmitted
to pathways such as Mitogen Activated Protein Kinase and Phosphatidylinositol 3-Kinase
(PI3K), thereby allowing cancer cells to survive molecular targeted therapies, undergo
epithelial to mesenchymal transitioning, and increase cellular invasion. Uncovering the crit-
ical crosstalk between the HER and Notch pathways can lead to improved screening for
the expression of these oncogenes enabling patients to optimize their personal treatment
options and predict potential treatment resistance. This review will focus on the current
state of crosstalk between the HER and Notch receptors and the effectiveness of current
therapies targeting HER-driven cancers.
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INTRODUCTION
Current research has revealed many interesting features of cell sig-
naling networks implicated in the development of breast cancer
and continues to define methods by which cancer cells become
able to exploit these networks to promote their growth, survival,
and invasiveness. Communication between cell signaling pathways
is critical to a cell’s response to an ever changing environment,
and is harnessed by cancer cells to progress their disease state
to obtain a growth advantage over healthy cells. Such pathways
include the Epidermal Growth Factor Receptor (EGFR) Tyrosine
Kinase (HER or HER) and Notch pathways, which have been
found to communicate with one another to overcome treatment
as well as promote Breast Cancer Stem Cell (BCSC) cell fate. This
review presents current perspectives on research of HER–Notch
crosstalk in breast cancer and culminates recent publications to
give an up-to-date view of the intricate mechanisms that describe
how communication between these two pathways is affecting the
development of malignancies, drug resistance, recurrence, and
metastatic progression.
BREAST CANCER AT A GLANCE
1. Breast cancer is the second leading cause of cancer-related death
among women worldwide. Women have a one in eight lifetime
risk of being diagnosed with breast cancer in the US alone (1).
Breast cancer is divided into four major subtypes based on
receptor overexpression during tumorigenesis as well as a pre-
invasive subtype known as ductal carcinoma in situ (DCIS).
The subtypes of breast cancer include: luminal A [estrogen
receptor (ER) +/ progesterone receptor (PR)+], luminal B
(ER+, PR+, HER2/HER2±), and triple negative/basal-like
(ER−, PR−, HER2−) (TNBC/BLBC) (2, 3). The luminal A, B,
and HER2+ breast cancer subtypes use estrogen/progesterone
and HER2 receptor overexpression and activation, respec-
tively, to drive tumor growth while the TNBC subtype lacks
comparable overexpression of these receptors (Table 1).
2. The luminal A and B breast cancer subtypes comprise 60–
70% of all breast cancers and are derived from the luminal
epithelium of breast ducts with cancer cells overexpressing the
ER and/or PR. First line therapy for the Luminal A and B
breast cancer subtypes are anti-hormonal therapies that target
estrogen-mediated activation of the ERα isoform. Aromatase
inhibitors (AI), tamoxifen, and fulvestrant are examples of anti-
estrogen therapies, with the luminal A subtype being more
sensitive to such inhibitors than the highly proliferative and
inherently more resistant luminal B breast cancer subtype.
The HER2/HER2+ breast cancer subtype has an amplifica-
tion of the HER2 gene. The HER2 gene is a proto-oncogene
and if mutated or overexpressed is a bonafide oncogene. HER2
amplification results in overexpression of the HER2 recep-
tor on the surface of breast cancer cell. The HER2+ subtype
occurs in 20% of breast cancers and is sensitive to HER2-
based-targeted therapies such as the humanized, monoclonal
antibody trastuzumab, or the small molecule tyrosine kinase
inhibitor, lapatinib. Mechanisms of action of these anti-HER2
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Table 1 | Breast cancer subtypes and therapies.
Subtype Molecular markers First line therapy Second line therapy Approximate
occurrence (%)
Reviewed in
reference
DCIS ER±HER2± Surgery, radiotherapy,
chemotherapy, none
Adjuvant to
chemo/radiotherapy such as
tamoxifen (ER+) or
trastuzumab (HER2+), none
20 Narod (4), Leonard
(5), Wiechmann (6)
Luminal A ER+/PR+ Tamoxifen (pre or post
menopausal)
Aromatase inhibitor (AI)
(post menopausal)
40 Ignatiadis (7),
Dawson (8)
Luminal B ER+/PR+/HER2+/Ki67 Tamoxifen (pre or post
menopausal)
Aromatase inhibitor (AI)
(post menopausal)
20 Ades (9)
HER2+ ±ER+/HER2+ Trastuzumab, pertuzumab Lapatinib 10 Baselga (10),
Zhang (11)
Triple negative
(TNBC)
EGFR/Notch-1/PI3K/-PTEN/-
claudins/Hsp90/Ras
Molecular targeted therapies
depending on subtype combined
with chemotherapy, surgery,
radiotherapy
Chemotherapy, surgery,
radiotherapy
10–20 Lehmann (12)
therapies will be expounded later in this review. Among others,
the TNBC/BLBC subtype does not express therapeutically tar-
getable ER, PR, or HER2 receptors making this aggressive sub-
type difficult to treat. Since TNBC lacks expression of targetable
receptors, treatment options for TNBC tumors are limited to
cytotoxic chemotherapy such as tubulin-destabilizing taxanes
(docetaxel, paclitaxel), DNA damaging alkylating/methylating
agents (Cyclophosphamide, Chlorambucil, Temozolomide), or
DNA untangling (topoisomerase II) stabilizers (doxorubicin,
camptothecin) aimed at killing highly proliferative TNBC cells.
3. Early stage Ductal Carcinoma In situ (DCIS) is a non-invasive
form of breast cancer in which luminal cells that line mammary
gland ducts are morphologically and physiologically changed
to resemble cancer cells, to some extent. If left untreated, DCIS
can proceed to a metastatic disease in three steps. First, a pop-
ulation of cells in the lesion begins to fill in the hollow luminal
space of the mammary duct. Second, these tumorigenic cells
can invade the surrounding breast tissue to become Invasive
ductal carcinoma. Third, the lesion becomes metastatic as the
cancer cells begin to access blood or lymph circulation to invade
distal parts of the body to form new tumors. If undiagnosed or
left untreated, DCIS has a two in three chance of progressing to
malignant disease (13). Molecular markers are similar between
DCIS and invasive breast cancer and these include ER+ and
HER2+. The expression of such markers can aid in determining
a proper treatment regimen for DCIS (5). Treatments can range
from molecular targeted therapies (tamoxifen, trastuzumab),
radiation, surgery (lumpectomy or mastectomy), to a combi-
nation of surgery, radiation, and molecular targeted therapy
with the end goal of breast conservation and reduced risk of
subsequent invasive or in situ tumor recurrence (14, 15).
4. There are many different mutations that can cause breast cancer
and this heterogeneity makes it a difficult disease to treat and
at times, diagnose. Dramatic improvements have been made
to treat and diagnose breast cancer with the best chance for
survival continuing to be early detection. Persistent research of
the inter-connected signaling pathways that cancer cells exploit
for continued survival and proliferation has led to many inter-
esting findings that may help improve breast cancer treatment.
This review delves into recent research exploring the role of
the Notch and HER/HER pathways in breast cancer and how
these potentially complementary pathways are able to commu-
nicate with one another to promote breast cancer and/or tumor
growth.
HER/HER PATHWAY
The HER/HER family is made up of four structurally related
receptor tyrosine kinases (RTKs) with the EGFR as the founding
member of the family. In humans, these include: HER1 (EGFR,
HER1), HER2 (Neu, HER2), HER3 (HER3), and HER4 (HER4).
HER2, the gene symbol, is derived from a homologous viral onco-
gene, Erythroblastic Leukemia Viral Oncogene, and has the official
name: V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene
Homolog or HER2 accordingly (16).
Activation of the HER/HER family of receptors requires bind-
ing of a soluble, growth factor-ligand located in the intracel-
lular cavity of the receptor that triggers receptor dimerization
and phosphorylation, and activation of downstream pathways
to elicit an appropriate response inside of the cell to the envi-
ronmental stimuli outside of the cell. EGFR is activated by
growth factor-ligands such as epidermal growth factor (EGF),
Heparin binding EGF (HB-EGF), amphiregulin (AREG), or trans-
forming growth factor alpha (TGF-α). In contrast, HER3 and
HER4 are activated by the heregulin (neuregulin) family of
growth factors (Hrg/Nrg 1, 2, 3, 4) (Figure 1A). Each HER/HER
receptor, upon activation by growth factor binding, initiates
hetero-dimerization or homo-dimerization of HER/HER recep-
tors (Figure 1B). HER/HER receptor(s) dimerization stimulates
auto-phosphorylation, followed by trans-phosphorylation of the
receptor partner. HER/HER phosphorylation occurs at specific
tyrosine residues within the intracellular domain of the HER/HER
receptors. The phosphorylation of HER/HER tyrosine residues
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FIGURE 1 |The HER receptor and pathway: (A) there are four members of
the HER family of RTKs: EGFR/HER1, HER2, 3, and 4. Each HER receptor is
composed of four functional extracellular domains (domain I, II, III, and IV) as
well as a tyrosine rich (Tyr) intracellular domain. Epidermal growth factor
(EGF), amphiregulin (AREG), heparin binding EGF (HB-EGF), and heregulin 1,
2, 3, 4 growth factor-ligands bind to domains II and III of EGFR/HER1 and
HER3, HER4, respectively. Growth factor-ligand binding initiates HER
conformational rearrangement causing exposure of the dimerization domain
(DD), which is sandwiched between domains II and IV, as well as allowing the
closed conformation of the HER receptor (portrayed by EGFR/HER1, HER3, 4)
to assume an open conformation (displayed by HER2). It is important to note
the truncated intracellular domain of HER3, which lacks kinase activity
therefore, the HER3 receptor is the kinase dead member of the HER family of
RTKs. (B) Ligand-mediated exposure of the dimerization domain enables the
binding of two like HER receptors to form a homo-dimer (left, EGFR–EGFR) or
two different HER receptors to form a hetero-dimer (right, HER2–HER3). It is
important to note that the HER2 receptor is in a fixed, open conformation and
does not require ligand binding to dimerize with a ligand bound HER receptor.
(C) Upon HER dimerization, the HER receptors undergo auto-phosphorylation
of their intracellular tyrosine residues. Auto-phosphorylation of the HER
receptors primes the receptors to transphosphorylate the tyrosine residues
of their binding partners (D) in preparation to initiate activation of downstream
targets (E) activated HER receptors initiate the AKT (left) and mitogen
activated protein kinase (MAPK) (right) pathways through a series of residue
targeted phosphorylations, or a phosphorylation cascade. The Src homology
domain 2 (SH2) of p85 (regulatory domain of PI3K) docks to the
phosphotyrosine residue of the activated HER receptor (EGFR). p85 docking
to EGFR enables Src homology domain 3 (SH3) of p110 (catalytic domain of
PI3K) to join the proline rich region (Pro) of p85 to initiate PI3K 3′
phosphorylation of phosphatidylinositol (4, 5)-bisphosphate (PIP2)
transforming PIP2 into phosphatidylinositol (3, 4, 5)-triphosphate (PIP3). PIP3
phosphorylation is aided by the Plekstrin homology domain (PHD) within the
catalytic domain of phosphoinositide dependent kinase-1 (PDK1). The lipid
binding PH domain recruits AKT to the plasma membrane where it docks to
PIP3 as the physical interactions and activations of PI3K, PTEN, PDK1, as well
as AKT occurs at the surface of the cell. PDK1 is able to phosphorylate AKT at
the Thr 308 residue as well as aid in PKCa activation. AKT phosphorylation
disrupts the formation of the tuberous sclerosis 1/2 (TSC 1/2) dimer, inhibits
hydrolyzation of the GTP binding protein, Ras homolog enriched in brain
(Rheb), to activate the mammalian target of rapamycin complex 1 (mTORC1)
complex as well as the mTORC2 complex. The mTORC1 complex is
composed of: G protein beta subunit-like (GβL), the metabolically sensitive
regulatory-associated protein of mTOR (Rptor), DEP domain-containing
mTOR-interacting protein (DEPTOR), and the serine/threonine kinase
mammalian target of rapamycin (mTOR). The fully formed mTORC1 complex
is able to promote cell growth, proliferation, and autophagy by directing
protein translation by mediating the ability of Rptor to recruit the formation of
the eukaryotic initiation factor 4F complex [eIF4F (eIF4E, G, B, etc.)] and
ribosomal protein S6 kinase beta-1 (S6K1). The mTORC2 complex is also
involved in cellular metabolism but mainly facilitates fluctuations in
cytoskeletal formation and degradation throughout the cell via serum
(Continued)
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FIGURE 1 | Continued
and glucocorticoid-regulated kinase 1 (SGK1), for instance. In a similar
fashion, the SH2 domain of growth factor receptor bound-2 (Grb2) protein
docks to the phosphotyrosine residue of the activated HER receptor
(HER2). SH2 interaction with the Grb2 scaffold protein initiates the binding
of two SH3 domains to the proline rich region of the son of sevenless
(SOS) protein. SOS is a guanine-nucleotide exchange factor (GEF) that acts
on Ras-GTPases (Ras-GDP) (rat sarcoma). SOS facilitates the unbinding of
guanosine diphosphate (GDP) from Ras, there by destabilizing Ras and
enabling guanosine triphosphate (GTP) binding to form Ras-GTP, and
initiate the MAPK phosphorylation cascade. A GTPase activating protein
(GAP) hydrolyzes Ras bound GTP (Ras-GTP), forming GDP, and halting
downstream phosphorylation of the MAPK pathway. Ras activation begins
the MAPK phosphorylation cascade, which is a series of serine/threoinine
specific protein kinases occurring on: rapidly accelerating
fibrosarcoma/mitogen activated protein kinase kinase kinase
(Raf/MAPKKK), mitogen/extracellular signal-related kinase/mitogen
activated protein kinase kinase (MEK/MAPKK), and extracellular
signal-related kinase 1/2/mitogen activated protein kinase (Erk1/2/MAPK).
Activation of the MAPK pathway initiates the transcription of a host of
genes including: c-Myc, c-Fos, and cyclins to orchestrate cell motility,
invasiveness, and proliferation.
categorizes the HER/HER family RTKs (Figures 1C,D). These
phosphorylated tyrosine residues recruit adaptor proteins such
as Grb2 and the p85 subunit of the PI3K complex, which elicit the
activation of several downstream pathways such as Protein Kinase
B (AKT/PKB) and the mitogen activated protein kinase (MAPK)
pathways (Figure 1E). HER/HER-mediated activation of down-
stream pathways enables a growth factor to elicit proliferation,
survival, or migration of the cancer cell (Reviewed in Bublil and
Kopan) (17, 18).
A significant number of ligand–HER receptor combinations are
engaged to maintain normal cell physiology during development
and throughout adult life. The mechanism of HER activation is
controlled by ectodomain shedding in which proteolysis is medi-
ated by a matrix metalloproteinase (MMP9 or ADAM12) that
cleaves the ligand growth factors from the surface of the cell,
near the transmembrane domain, to release the soluble ligand into
the extracellular environment (19). All four members of the HER
family of RTKs share structural similarities, but they have spe-
cific features that confer unique regulatory characteristics. Unlike
EGFR, the extracellular region of HER2 resembles a ligand acti-
vated or fixed state, making HER2 an orphan receptor, thus not
needing to bind ligands for its activation (20, 21). HER3 does
not possess kinase activity and can only potentiate downstream
signaling when dimerized with another HER receptor. The fixed
state of HER2 makes it the preferred dimerization partner of the
other HER receptors, particularly HER3. In addition, HER2 has
been shown to dimerize with other RTKs, such as the Insulin-
like Growth Factor-1 Receptor (IGF-1R) (22). HER2 dimerization
enables HER receptors to broaden their ligand binding specificity
as the HER ligands have non-overlapping functions, which restrict
their binding to specific HER receptors (23–25). For example,
only one EGF ligand is needed for downstream pathway activation
when bound to EGFR and hetero-dimerized with HER2.
Epidermal growth factor receptor overexpression, or consti-
tutive activation, has been implicated in the progression of a
variety of cancers including lung, head and neck, colon, brain,
and breast cancer by promoting tumor angiogenesis and metasta-
sis (10, 26–31). EGFR inhibitors such as gefitinib (32) and erlotinib
are tyrosine kinase inhibitors (TKIs). TKIs have been able to reduce
EGFR oncogenic activity in some cases (33). Anti-EGFR mon-
oclonal antibodies, such as cetuximab, bind to the extracellular
domain of EGFR to inhibit growth factor binding and subsequent
activation of downstream pathways (34).
HER2’s oncogenic activity confers a strong proliferative advan-
tage to tumor cells, which includes increased tumor size, lymph
node invasion, aneuploidy, percentage of cells in S-phase, and
tumor grade resulting in an overall increased aggressiveness of
the tumor (35–37). HER2 overexpression has been implicated in
several human solid tumors including breast cancer in which a
majority of the HER2 oncogenic activity, and its inhibition, has
been studied. HER2 gene amplification and subsequent HER2
protein overexpression occurs in 15–25% of DCIS (38) and inva-
sive forms of HER2+ breast cancer. HER2 has been shown to
increase p53 expression through an unknown mechanism in skin
squamous-cell carcinoma (39). HER2 induction of p53 expres-
sion in HER2+ breast cancer cells may attribute to changes in
Cyclin Dependent Kinase (CDK)/cyclin activity to promote cell
division. Targeted anti-HER2 therapy includes the use of the anti-
body, trastuzumab, as well as TKIs, such as lapatinib. Trastuzumab
is a humanized monoclonal antibody that binds to domain IV of
the HER2 extracellular region causing reduced activation of the
HER2 receptor (Figure 1A). Both anti-HER2 targeted therapies
are potent inhibitors of HER2 activation in HER2+ tumors caus-
ing reduced disease progression (40). TKIs such as gefitinib and
lapatinib are not strictly targeted to the tyrosine kinase activity
of EGFR or HER2 alone but can affect the activity of both HER
receptors.
An important trait of the HER family of receptors is the acti-
vation of the AKT/PKB and the MAPK pathways via HER phos-
phorylation. HER-mediated activation of PI3K causes the phos-
phorylation of the serine/threonine-specific protein kinase, AKT,
which in turn activates mammalian Target of Rapamycin (mTOR).
mTOR is comprised of two complexes: mTORC1 and mTORC2
and this review will focus on the ability of mTORC1 to induce
protein synthesis that stimulates cell proliferation, migration, and
metabolism (Reviewed in Altomore) (41). Many components of
the AKT pathway have been implicated in tumorigenesis events
such as the oncogenic activity of PI3K and the loss of the tumor
suppressive activity of protein “Phosphatase and tensin homolog
deleted on chromosome TEN (PTEN)”. These mutations have
been suggested to drive cancer growth. Due to AKT’s role in a
variety of human solid tumors and hematological malignancies,
several therapies have been developed to target components of the
AKT pathway to reduce tumor survival such as: Wortmannin and
LY294002, which are reversible and non-reversible inhibitors of
PI3K, respectively. HER activation of the MAPK pathway via dock-
ing of the Grb2 adaptor protein to HER phosphorylated tyrosine
residue induces a Ras-mediated phosphorylation cascade result-
ing in the transcription of a number of genes that promote cell
proliferation, survival, and cell migration (reviewed in Hynes)
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(42). Similar to the AKT pathway, several components of the
MAPK pathway are involved in promoting tumorigenesis making
these two pathways central nodes where activating mutations are
known to trigger tumorigenesis and metastasis. Several inhibitors
were designed to target components of the MAPK and mTOR
pathways such as: U0126 and rapamycin, which inhibit Mito-
gen/Extracellular signal-related Kinase/Mitogen Activated Protein
Kinase Kinase (MEK/MAPKK) and mTOR, respectively. EGFR
or HER2-mediated stimulation of cell proliferation and survival
pathways can cause cancer cells to become dependent on these
pathways, or “addicted,” to EGFR or HER2 expression to maintain
tumor growth and survival (43).
Unfortunately, cancers become resistant to many types of ther-
apies that specifically target EGFR, HER2, or components of their
downstream pathways. Resistance to these targeted treatments
leads to tumor recurrence and in some cases a more aggressive
cancer, ultimately ending in death of the patient. Cancer cells can
adapt to treatments using a variety of mutations that enable the
cancer cell to overcome targeted therapies and enable them to
propagate under such conditions. It has come to light that can-
cer cells are able to become resistant to therapies by recruiting the
use of a similar, compensatory pathway that continue downstream
activation of protein synthesis, i.e., the AKT pathway, and/or tran-
scriptional up-regulation of survival genes mediated by the MAPK
pathway. Using compensatory pathways to divert dependence from
one receptor to another is referred to as crosstalk, or bidirectional
communication, between two pathways to allow continued cancer
cell growth and survival. Extensive research has been done in G-
Protein Coupled Receptor (GPCR) crosstalk with EGFR/HER2
as some GPCR agonists such as Lysophosphatidic acid (LPA),
carbachol (muscarini acetylcholine inhibitor), and thrombin are
known to be able to increase HER activation in two different ways
(reviewed in Bray) (44). The first consists of a GPCR-dependent
increase in the ectodomain shedding of HER ligands. The sec-
ond phenomenon includes GPCR activation of c-Src to mediate
phosphorylation of HER tyrosine residues. HER activation via
GCPR may be required for GPCR-mediated mitogenic activity
via the MAPK pathway (45). Both HER–MAPK pathway initia-
tion, as well as activation of number of steroid hormones, can
trigger the transcription of HER ligands and evidently initiate
a positive feedback loop. Mechanisms of crosstalk between the
HER family of RTKs and several other pathways including the:
Wnt/β-catenin (46), TNFα/IKK/NK-κB (47, 48), and Notch path-
way (49, 50) have been under thorough investigation for several
years. Interesting findings have been made, which describe the
novel mechanisms of HER–Notch bidirectional crosstalk. Recent
data illustrate how these new mechanisms of crosstalk have been
implicated in treatment resistance, mechanisms of Epithelial to
Mesenchymal Transitioning (EMT), as well as the propagation
and survival of BCSCs.
NOTCH PATHWAY
The Notch receptor is a single-pass, type I, transmembrane recep-
tor (Reviewed by Kopan et al.) (Figure 2A) (51). A mature Notch
receptor is formed as a hetero-dimer, composed of two domains
bound by a non-covalent bond, typically mediated by calcium
(Ca2+). Upon maturation, the full length Notch polypeptide is
cleaved at the S1 site, within the Golgi-apparatus by a furin-like
convertase, into two domains: the Notch extracellular (NECD)
and transmembrane/intracellular (NTMICD). The extracellular
portion of the Notch receptor contains a series of EGF-like repeats
that mediate ligand interactions from a neighboring cell. The EGF
repeats are followed by the Negative Regulatory Region (NRR)
that prevents ligand-independent activation of the Notch recep-
tor. There are five known Notch-ligands: Jagged-1 and -2 (Jag-1,
-2), Delta-Like-1, -3, and -4 (DLL-1, -3, -4) that bind to and
activate the Notch receptor when two neighboring cells are in
close proximity to each other (Figure 2C). The affinity of a
Notch-ligand to its Notch receptor can be attenuated by Fringe
glycosyltransferases (Lunatic, Manic, or Radical) by adding N -
acetylglucosamine moieties to the NECD region. The intracellular
domain of the Notch receptor contains the active portion of the
Notch receptor, the Notch Intracellular Domain (NICD), which
is composed of the: RBP-Jκ associating module (RAM) domain,
ankyrin domain, Cysteine Response region (NCR), Transacti-
vation Domain (TAD), proline/glutamic acid/serine/threonine-
rich motifs (PEST domain), and a pair of Nuclear Localization
Sequences (NLS) that sandwich the Ankyrin domain to direct
cleaved NICD to the nucleus enabling NICD to initiate transcrip-
tional activation of target genes. Activation of the Notch pathway
requires a series of events, which begins with the Notch receptor on
a signal receiving cell binding to a Notch-ligand on the neighboring
signal sending cell. Consequently, this ligation of ligand to receptor
is required for removal of the inhibitory NECD from the NTMICD
causing two subsequent cleavages at S2 mediated by ADAM10/17
and S3/4 mediated by the γ-secretase complex. The ADAM and
γ-secretase targeted cleavage sites are buried within the trans-
membrane domain of the Notch Extracellular Truncation (NEXT)
fragment. Cleavage by the γ-secretase complex releases the NICD
portion of the Notch receptor (Figure 2A). NICD shuttles to the
nucleus where it acts as a Recombining Binding Protein-Jκ/Core
Binding Factor-1 (RBP-Jκ/CBF-1) mediated transcriptional acti-
vator of target genes. NICD binds to CBF-1,which is already bound
to DNA, enabling the release of negative co-regulatory proteins
such as C-terminal-Binding Protein 1 (CtBP1) and SMRT/HDAC-
1-Associated Repressor Protein (SHARP) and the recruitment
of co-activating proteins such as Mammal Mastermind-like-1
(MAML-1) and the Histone Acetyltransferase (HAT), p300, to
CBF-1, to form the Notch transcriptional activating complex.
Canonical Notch target genes are primarily basic helix-loop-helix
transcriptional repressors including, Hairy/Enhancer of Split-1
(HES-1-5) and Hairy/Enhancer of split with a unique YRPW
motif-1 (HEY-1, HEY-L) (Figure 2C). There are four Notch par-
alogs (Notch-1, -2, -3, -4) each with quite different structures and
possibly synergistic and/or counteracting functions (Figure 2B).
The Notch pathway is most commonly associated with lateral
inhibition in which the Notch-ligand, Delta, if expressed in one
cell can inhibit Delta expression by a neighboring cell. In a clus-
ter of undifferentiated cells, when one cell begins to develop into
an epithelial cell, it signals its neighbors to do the same. Initially,
an undifferentiated cell expresses both the Notch receptor and
the Delta ligand. Activation of the Notch receptor inhibits Delta
production in the same cell. Through juxtacrine signaling, neigh-
boring cells compete to produce Delta, resulting in a feedback
www.frontiersin.org December 2014 | Volume 4 | Article 360 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baker et al. Notch-EGFR/HER2 bidirectional crosstalk in breast cancer
FIGURE 2 |The Notch receptor and pathway. (A)The Notch receptor is
composed of several domains that can be divided between the extracellular
domain (NECD) and the transmembrane and intracellular domain (NTMICD).
The NECD begins at the N-terminus (NH3) end of the Notch receptor and
contains ligand binding epidermal growth factor-like (EGF) repeats and the
negative regulatory region (NRR). Fringe proteins target the EGF repeats for
glycosylation, which can augment their ligand binding ability to the Notch
receptor. The NRR is composed of Lin12-Notch repeats (L) and the
heterodimerization domain (HD), which aid in maintaining a closed
conformation of the Notch receptor until ligand binding. The NTMICD
contains: the transmembrane domain (T, TMB), the RBP-Jκ associating
module (R) or RAM domain, one of two nuclear localization signals (N), the
ankyrin domain, a second nuclear localization signal, the cysteine response
region (NCR), the transactivating domain (TAD), and a proline/glutamic
acid/serine/threonine-rich motif (PEST) at the C-terminal (COOH) end of the
Notch receptor. Ligand bound Notch is cleaved at a series of scissile sites (S1,
2, 3, 4), which are represented just outside of (S1) and inside the
transmembrane domain (S2, 3, 4) (TMB enlargement). Furin-like convertase
cleaves immature Notch at S1 to create the mature, heterodimeric Notch
receptor, which is stabilized by a non-covalently bound calcium ion (Ca). The
RAM domain facilitates core binding factor-1 (CBF-1) binding, the ankyrin
domain binds mammal-like mastermind-1 (MAML-1) and p300 (p300), which
are necessary components of the Notch transcriptional activating complex.
The PEST domain is responsible for degradation of the Notch intracellular
domain (NICD). (B). There are four Notch receptor paralogs, each similar in
overall composition but with slight structural differences that facilitate their
diverse attributes. From top to bottom are Notch-1, -2, -3, and -4. Notch-1 is
the most studied Notch receptor containing all of the above mentioned
domains with 36 EGF-like repeats. Notch-2 is similar to Notch-1 except for
differences in its EGF-like repeats as well as the ability of Notch-2 to bind to
Jagged-1 upon fringe modification (118). Notch-3 has a slightly truncated
EGF-like domain with 34 repeats and lacks a transactivating domain. Notch-4
is the smallest of the Notch receptor paralogs with 29 EGF-like repeats, a
shorter NICD due to a lack of a transactivating domain and cysteine response
region, as well as the addition of a PDZ-Domain [Post-synaptic Density Protein
(PSD)-95] (PDZ) that plays a critical role in proper neuronal development (119).
(C)The Notch pathway is activated by a Notch-ligand (jagged-1, -2, DLL-1, 3, 4)
expressed on a signal sending cell binding to a Notch receptor (Notch 1, 2, 3,
4) on a signal receiving cell. Ligand bound Notch undergoes a series of
cleavages, first by a disintigrin and metalloproteinase/tumor necrosis factor
alpha converting enzyme (ADAM/TACE) at the S2 cleavage site to form the
Notch extracellular truncation (NEXT) fragment. The NEXT fragment is
targeted by the γ-Secretase complex for cleavage. The γ-secretase complex is
composed of nicastrin, anterior PHarynx-defective 1 (APH-1), presenilin
ENhancer 2 (PEN-2), and the active component of the complex, presenilin-1.
γ-Secretase is inhibited by γ-secretase inhibitors (GSIs), which prevent Notch
cleavage and transcriptional activation. Proper cleavage of the Notch receptor
releases NICD, allowing NICD to travel to and enter the nucleus where NICD
binds to promoter bound CBF-1, allowing CBF-1 to release negative
co-regulators (NCoR) and recruit transcriptional co-activators. NICD-mediated
transcription cannot occur without the recruitment of mammalian
mastermind-like-1 (MAML-1) and the histone acetyltransferase, p300, to
unwind the compressed DNA allowing transcription of the Notch targeted
genes. Notch activates the transcription of canonical target genes such as:
hairy enhancer of split-1 (HES-1), hairy/enhancer of split with an YRPW
motif-1 (HEY-1), and non-canonical Notch target genes such as survivin.
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loop that drives the two neighboring cells to assume different cell
fates based on the number of Notch receptors or Delta ligands
expressed by each cell. Notch signaling is used to establish a bor-
der between two different populations of cells such as stromal and
progenitor cells. Boundary formation by oscillating Notch activity
is most notable in somite formation in which the constant activa-
tion and inactivation of Notch-mediated transcriptional activity
causes the segmented formation of somites in vertebrates (52–54).
Notch is able to dictate cell lineage by asymmetrical inheritance of
Notch regulators between two dividing, daughter cells, and is most
evident during neurogenesis (55). Protein encoded by the gene
NUMB (Numb Drosophila Homolog), is an inhibitor/negative
regulator of Notch activity. Asymmetric distribution of Notch and
Numb between two dividing cells determines if one daughter cell
is a signal sending cell and if the other is a signal receiving cell.
This uneven distribution of Notch and Notch regulators, Numb,
is passed down through multiple cell divisions to maintain stem
cell populations as well as influence cell lineage decisions (56). The
culmination of the Notch receptor studies resulted in determining
the Notch pathway and its ability to act as a form of short range
communication between cells. Notch juxtacrine signaling has been
found to be involved in a variety of processes, most notably in
stem cell differentiation, self-renewal, and cell fate determination
as well as cell proliferation, growth, and survival (Reviewed by
Artavanis-Tsakonas) (57).
The Notch pathway has been referred to as the Notch-survival
pathway due to promotion of cell growth and proliferation. One of
the Notch gene targets responsible for regulation of cell longevity
is called survivin. Survivin is an Inhibitor of Apoptosis Protein
(IAP) and functions to down-regulate caspase 3, 7, and 9 apoptotic
activity as well as regulate the cell cycle by interacting with spin-
dle microtubules during mitosis (58). Cyclin Dependent Kinase-1
(CDK1) phosphorylates the threonine 34 residue of survivin to
stabilize its protein structure (59, 60) and enabling survivin to
escape degradation mediated by the X-linked IAP-X-linked Asso-
ciating Factor-1 complex (XIAP-XAF1). The XIAP-XAF1 complex
induces E3 ligase activity that targets survivin for ubiquitina-
tion and subsequent proteasomal degradation. Prolonged survivin
expression has been associated with breast cancer cell survival via
the MAPK/ERK and AKT/PI3K pathways (61). A correlation has
been made between poor breast cancer prognosis and an increase
in the expression of both Notch-1 and survivin in ER-breast cancer
and has been described as the Notch-Survivin signaling axis (62).
There is a growing body of evidence that Notch up-regulation
or mutation results in several events that enable breast cancer
cells to: become resistant to targeted treatments, undergo EMT,
metastasize, and promote BCSC survival, and self-renewal (63).
Increased co-expression of Notch-1 and Jagged-1 has been associ-
ated with poor prognosis for women diagnosed with breast cancer
(64). Notch-1, -3, or -4 have shown oncogenic activity in T cell
acute lymphoblastic leukemia (T-ALL) (65), B-cell lymphoma
(66), cervical (67), colon (68, 69), lung (70), and ovarian (71, 72)
cancers while, surprisingly, Notch-2 has displayed tumor suppres-
sive activity in some breast cancer subtypes (73–75). There are a
number of studies characterizing Notch as a tumor suppressor in
some myeloid malignancies (76, 77). Notch targeted treatments
include γ-Secretase Inhibitors (GSIs), which inhibit proteolytic
processing and subsequent NICD-mediated transcriptional acti-
vation by two different modes of action. First, transition state
analog GSIs mimic the transition state of a substrate that is cleaved
by γ-secretase thereby binding to the catalytically active subunit
of γ-secretase, presenilin-1, to inhibit GSI-mediated cleavage of
a substrate, such as NEXT (Figure 2C). Second, non-transition
state analog GSIs are small molecule inhibitors that bind to the
γ-secretase in an allosteric manner (regulate GS enzymatic activ-
ity by not binding to the active site of GS), to interfere with its
ability to cleave and activate the Notch receptor (78) (Reviewed
by Olsauskas-Kuprys) (79). There are several distinct GSIs (DAPT,
MRK-003, Compound E) as well as the continued development of
selective Notch inhibitors,γ-secretase modulators (PF-03084014),
which are able to inhibit specific Notch paralogs (80). Continued
research into the role of the Notch pathway in tumorigenesis has
revealed novel crosstalk with the EGFR and HER2 receptors in a
variety of solid tumors, including breast cancer.
NOTCH–EGFR CROSSTALK
Researchers have continued to elucidate crosstalk between Notch
and EGFR in hopes to dissect the mechanism(s) by which this
crosstalk occurs and to better comprehend how cancer cells use
the Notch pathway to compensate for EGFR targeted inhibition.
Crosstalk between the Notch and EGFR signaling pathways has
been observed in the Drosophila eye and wing development in
which the two pathways can promote or antagonize each other to
select which phenotype is produced, depending on the develop-
mental context (81–83). Research into the role of the Notch–EGFR
crosstalk has since been observed in lung (70), skin (84), and
brain (85) cancers. Current investigation of the bidirectional com-
munication between EGFR and Notch led to its observation in
non-small cell lung cancer by Xie et al. as a route of acquired
resistance to EGFR targeted TKIs and development of the EMT
phenotype via Notch-1 mediated down-regulation of E-cadherin
(epithelial marker), as well as up-regulation of vimentin (mes-
enchymal marker), and Snail (mesenchymal marker) expression
(86). Notch–EGFR crosstalk has been shown to increase MUC5AC
expression (87) causing increased goblet cell secretion of mucin,
a feature attributed to chronic airway inflammatory disease as
well as a potential activator of inflammatory induced lung can-
cer. EGFR has been shown to inhibit expression of the Notch-1
gene in a squamous-cell carcinoma model by up-regulating c-Jun,
which in turn down-regulates p53, causing repression of Notch-1
transcription, and this form of Notch-1-EGFR crosstalk occurs via
the MAPK/MEK/ERK pathway (84). These are just a few examples
of Notch–EGFR crosstalk promoting drug resistance, EMT, and
disease progression in various carcinomas.
Activation of the PI3K pathway by deletion or inactivation of
PTEN or oncogenic mutation of PIK3CA has been observed in
many types of cancer as well as being implicated in drug resistance.
Down-regulation of PTEN and oncogenic mutation of PIK3CA
compounded with EGFR over expression has been correlated with
poor response to trastuzumab treatment as well as a poor clinical
outcome in women with HER2+ breast cancer (88, 89). While
PI3K is a downstream target of EGFR signaling, growing evidence
suggests that Notch activates the PI3K pathway to promote sur-
vival. The regulation of the PI3K pathway by Notch has been shown
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by Palomero et al. Specifically, the transcriptional target of Notch-
1, HES-1 has been shown to repress PTEN expression resulting
in increased PI3K signaling in T-ALL (90). Furthermore, Jagged-
1-mediated activation of Notch signaling was shown to increase
the phosphorylation and thus the activation status of AKT1 in
cervical cancer cell lines to promote EMT and increase cell motil-
ity (91). Previous studies have shown that inhibition of the PI3K
pathway, using small molecule inhibitors that target AKT or the
mTOR signal transduction pathway, are able to restore sensitivity
to trastuzumab treatment (92). Similarly, Eichhorn et al. showed
that the use of a dual PI3K and mTOR inhibitor, NVP-BEZ235, can
reverse anti-EGFR/HER2 resistance in HER2+ breast cancers that
express low PTEN or contain PIK3CA activating mutations (93).
These results strongly indicate that both Notch and EGFR activate
the PI3K pathway suggesting that the two pathways converge to
promote proliferation and survival.
Hyperactivation of both the Notch and EGFR pathways were
observed in TNBC cells by Dong et al. leading them to hypoth-
esize that Notch–EGFR crosstalk occurs in this aggressive breast
cancer subtype (94). Inhibition of EGFR or Notch alone was insuf-
ficient to reduce TNBC tumor burden, leading to the possibility
that these complementary pathways are capable of interacting with
one another to confer resistance to EGFR or Notch targeted ther-
apies, hence bidirectional crosstalk between the EGFR and Notch
pathway. Therefore, combined Notch (DAPT, Compound E) and
EGFR (gefitinib) inhibition caused a decrease in TNBC cell pro-
liferation and an increase in TNBC cell death both in vitro and
in vivo indicating that a synthetic lethal relationship exists between
the EGFR and Notch pathways. Furthermore, the AKT pathway
has been shown to promote resistance to Notch inhibition (95,
96) as well as resistance to EGFR inhibition (97–99). Inhibition
of EGFR or Notch receptors alone has little effect on the activity
of AKT, but dual inhibition showed dramatically reduced level of
serine-473 phosphorylation of AKT in vitro. Overexpression of
NICD1 in the EGFR expressing TNBC cell line, HCC1806, caused
resistance to combined DAPT and gefitinib treatment indicat-
ing that the Notch–AKT pathway confers resistance to combined
EGFR and γ-secretase inhibition in this TNBC model. Unfortu-
nately, all TNBCs do not have the same mutation profiles and
some lack overexpression of EGFR. Importantly, a large group of
TNBC malignancies with low EGFR expression are not affected
by anti-EGFR or anti-Notch treatments, as seen by in vitro studies
performed in MDA-MB-231 with a K-Ras mutation (100, 101)
(Figure 3). These results indicate a bidirectional crosstalk between
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FIGURE 3 | Notch–EGFR crosstalk inTNBC. Dong et al.
ascertained a form of crosstalk between EGFR and Notch receptors
that enabled resistance to EGFR targeted therapy, gefitinib, in TNBC
cells. It is proposed that EGFR targeted resistance occurs by
Notch-1-mediated activation of the AKT pathway. Notch–EGFR
crosstalk facilitates an increase in serine-473 residue
phosphorylation of AKT, which allows TNBC cells to survive EGFR
targeted treatments. Dual inhibition of EGFR via the tyrosine kinase
inhibitor (TKI) gefitinib and the Notch pathway by GSIs, N-[N-
(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT)
in vitro, and compound E in vivo, are synergistically lethal to TNBC
tumorigenesis.
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Notch and EGFR occurs in breast cancer. Clear evidence provided
shows that both Notch and EGFR pathways are used by TNBC cells
to escape targeted inhibition by compensatory activation of the
Notch pathway. Compensatory Notch pathway activation main-
tains MAPK and/or AKT downstream signaling pathways making
the breast cancer cell resistant to EGFR targeted treatment. Pre-
clinical studies have combined EGFR and HER2 inhibitors with
MAPK/MEK or AKT/PI3K/mTOR inhibitors to reduce resistance
to EGFR/HER2 TKIs (92, 93, 102). One mechanism that has been
proposed is that EGFR regulates the Notch pathway through the
repression of the global transcriptional co-repressor, Goucho/TLE
(Transducer like Enhancer of split) (103) to attenuate Notch-
mediated gene activation and promote growth of cancer cells.
EGFR targeted inhibition alone has been an ineffective treatment
strategy for TNBC and understanding the mechanisms of EGFR
resistance as well as improving therapeutic strategies for TNBC are
critical areas of research to improve survival rates for these women.
Dual targeting of the EGFR and Notch pathways may become a
viable treatment option for women diagnosed with EGFR over
expressing TNBC.
NOTCH–HER2 CROSSTALK
Notch–HER2 crosstalk was first identified in breast cancer cells
by Osipo et al. who observed that HER2+ breast cancer cells had
low Notch-1 expression and activation. Upon treatment with an
anti-HER2 therapy (trastuzumab), or observing HER2+ cells with
an acquired resistance to an anti-HER2 therapy, it was noted that
Notch-1 expression and Notch transcription of canonical target
genes increased (50). This important research described siRNA
knockdown or GSI-mediated inhibition of Notch-1 enhanced
trastuzumab sensitivity and reversed resistance to trastuzumab
treatment in vitro. These findings led to the conclusion that HER2
inhibition increased Notch-1 activity in a compensatory manner
to promote survival and resistance of HER2+ breast cancer cells.
Combinatorial targeted treatment of Notch and HER2 signaling
pathways not only inhibited HER2+ tumor formation but more
importantly recurrence (104).
One mechanism by which HER2 restricts Notch signaling was
identified by Ju et al. These investigators showed that HER2
overexpressing breast cancer cells activate the ERK pathway to
block the activity of the γ-secretase complex thus resulting in
reduced levels of NICD1. Interestingly, these investigators also
showed that Notch-1 is a transcriptional repressor of the Sur-
vivin gene, a potent anti-apoptotic gene that is regulated at the
protein level by the E3 ligase complex, XIAF1:XIAP. Specifically,
Ju et al. showed that the HER2–ERK axis represses XIAF1, which
is required to ubiquitylate the survivin protein. This resulted in
increased survivin protein stability to promote survival of HER2+
breast cancer cells. Therefore, these results suggest that HER2
signaling via ERK inhibits Notch-1 cleavage thus limiting the
formation of NICD1 and stabilizes the survivin protein (105)
(Figure 4).
Conversely, crosstalk between HER2 and Notch could be stim-
ulatory rather than inhibitory. One of the first studies to implicate
crosstalk between Notch-1 and HER2 was published by Chen
et al. where they showed that the HER2 promoter contained a
putative CBF-1 binding site (106). Specifically, these investigators
demonstrated that overexpression of NICD1 induced transcrip-
tion of HER2 suggesting that Notch-1 positively regulates HER2
expression. Moreover, Notch has been shown to regulate HER2
expression in BCSCs thereby controlling the survival and differ-
entiation of BCSCs (107), which have been implicated in promot-
ing breast cancer cell drug resistance, metastasis, EMT, as well
as tumor recurrence and growth. Furthermore, Pradeep et al.
demonstrated that HER2 overexpression in MCF-10A-DCIS cells
increased Notch-3-mediated transcription of Notch target genes
to promote a more malignant phenotype (108). In the HER2+
DCIS cell model, Notch-3 nuclear localization was increased along
with ADAM17, presenilin-1, Jag-1, DLL-1, and Notch-1, all com-
ponents of the Notch pathway. Knock down of Notch-3 reduced
HER2+DCIS cell proliferation, spheroid formation, and luminal
spheroid filling indicating that HER2-mediated up-regulation of
Notch-3 promoted HER2+ DCIS cell proliferation and survival.
Findings by Pradeep et al. imply that HER2-mediated activation of
Notch-3 is necessary during the early steps of mammary tumori-
genesis and targeted inhibition of these pathways can reduce
early tumor progression in DCIS-HER2+ cancers with Notch-3
overexpression.
Combined inhibition of Notch and HER pathways, EGFR or
HER2 via gefitinib or lapatinib, respectively has been investigated
in a DCIS model by Farnie et al. to deduce the effects of dual
inhibition of the Notch–EGFR/HER2 pathways on DCIS stem
cells (109). Using a 3D culture system to assess luminal filling
of DCIS acini as well as DCIS Cancer Stem Cell (CSC) activity,
two DCIS cells lines, SUM225 (HER2−), and MCF10DCIS HER2
(HER2+), as well as human primary DCIS samples (HER2±)
were studied. These two cell lines were treated with GSI (DAPT)
and/or anti-HER1/2 (gefitinib or lapatinib) therapies to deduce the
role of Notch–EGFR/HER2 crosstalk in HER± DCIS breast can-
cer. Anti-Notch treatment reduced mammosphere formation and
acini size in the HER2+ cells yet had no effect on the HER2− cells.
Anti-EGFR/HER2 treatment had the opposite effect by reducing
mammosphere formation and acini size on HER2− cells with
no effect on the HER2+ cells. Interestingly, combined inhibi-
tion of the Notch and EGFR/HER2 receptors reduced both acini
size and mammosphere formation regardless of HER2 expres-
sion indicating that the crosstalk between Notch and EGFR/HER2
receptors maintains BCSC survival and self-renewal (Figure 5). In
addition to these studies, others have shown that HER2 may facil-
itate increased expression of components of the Notch pathway
such as Notch-ligands (Jag-1, Jag-2, DLL-1) or Notch activating
metalloproteinases (ADAM, presenilin-1).
Notch–HER crosstalk can involve upstream and/or down-
stream components of either pathway. Recent data have shown
Notch-dependent up-regulation of the ADAM12 metallopro-
teinase causes an increase in ectodomain shedding of HB-EGF,
an EGFR growth factor, in head and neck squamous-cell carci-
noma cells under hypoxic conditions. Notch-mediated release of
HB-EGF causes the formation of invadopodia to aid in cancer cell
invasion (110). Notch–EGFR crosstalk has been implicated as a
paracrine mediator of estrogen to promote ER−/ER low BCSC
survival and proliferation within ER+ breast cancer cell lines
and patient samples (111). Recent data have shown that estro-
gen increases ER+ bulk cell (Non-BCSC) production of EGFR,
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FIGURE 4 | Notch–HER2 crosstalk in HER2+ BC (A). Ju et al. determined an
intricate form of crosstalk between HER2 and Notch-1 in HER2+ breast
cancer. HER2+ breast cancer cells exhibit an increase in survivin protein
expression concomitantly with a decrease in survivin mRNA expression.
HER2 promotes activation of the AKT pathway, which threonine 308
phosphorylated AKT can inhibit p21-mediated inhibition of cyclin dependent
kinase-1 (CDK1) dimerization to cyclin B1. Concomitantly, HER2-mediated
activation of the MAPK pathway enables Erk-mediated CDK1-Cyclin B1
dimerization as well as inhibition of ubiquitination and proteasomal
degradation of survivin by restricting the formation of the X-linked Inhibitor of
apoptosis protein-X-linked associating factor-1(XIAP-XAF-1) complex. Together,
AKT and Erk promote dimerization of CDK1 to Cyclin B1, which stabilizes
survivin by phosphorylating the threonine 34 residue (Thr34) of the survivin
protein. Increased survivin stabilization causes an increase in survivin
expression. Survivin mRNA is reduced by Erk-mediated inhibition of
γ-secretase, which in turn inhibits Notch receptor-mediated transcriptional
activation. (B) Pradeep et al. established an interesting form of crosstalk
between the HER2 and Notch-3 receptors in HER2+ DCIS. HER2
up-regulates the transcription of the Notch pathway components: jagged-1, -2
(Jag-1/2), DLL-1, ADAM17, presenilin-1 (Pres-1), as well as Notch-3 and
Notch-1 (Notch-3/1) through the MAPK pathway. Increased transcription of
the Notch pathway components causes Notch-mediated up-regulation of
c-Myc, Cyclin D1, phosphorylation of Serine-473 of Atk (+P-Ser 473 AKT), and
down-regulation of the tumor suppressor, PTEN. Combined GSI and
trastuzumab (Trast) treatment reduce HER2+ DCIS cell survival and
invasiveness.
FGFR, and Notch-ligands, which are able to regulate ER−/ER low
BCSC differentiation and expansion via the EGFR/MAPK/ERK,
FGF/FGFR/Tbx3, and DLL-Jag/Notch/Pea3 pathways. Estrogen-
driven BCSC regulation can be inhibited by blocking estrogen
using tamoxifen, EGFR using gefitinib, or Notch using a GSI to
attenuate BCSC survival and early progenitor cell differentiation,
and possibly de-differentiation, respectively. Crosstalk between
EGFR, FGFR, and Notch pathways are responsible for estrogen
induced changes in the ER−/ER low BCSC population and may
play a role in endocrine resistance as well as offer suitable targets
for the treatment of ER+ breast tumors. Combinatorial drug
treatments simultaneously targeting Notch and EGFR receptors
continue to be assessed to reduce the occurrence of chemo-
resistance in cancers such as glioblastoma. Sooman et al. treated
six glioblastoma cell lines with drugs such as imatinib (TKI),
camptothecin, or temozolomide, and measured gene expression
using microarray to identify molecular pathways associated with
drug resistance, then combined the cytotoxic treatments with tar-
geted inhibitors to determine optimal combinatorial treatments
for glioblastoma (112). Synergistic effects of camptothecin with
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FIGURE 5 | Notch–HER2 crosstalk in HER2+ DCIS. Farnie et al. discerned
a form of Notch–EGFR/HER2 bidirectional communication in an in vitro
DCIS breast cancer model that promoted acinar size and mammosphere
(BCSC) formation. Dual inhibition of the Notch–EGFR/HER2 receptors using
DAPT (GSI) and gefitinib/lapatinib, respectfully, caused decreased acinar
size and mammosphere formation while either inhibitor alone effected only
acinar size or only mammosphere formation.
gefitinib or NSC 23766 [ras-related C3 botulinum toxin substrate
1 inhibitor (RAC1)], as well as imatinib with DAPT or NSC 23766
and additive effects of temozolomide with gefitinib or PF-573228
(focal kinase inhibitor) to sensitize glioblastoma cells to cytotoxic
chemotherapy causing cancer cell death and growth arrest. Careful
consideration of the effect of these drug combinations on non-
cancerous epithelial cells was taken and the analyses presented
potential gene expression signatures that correlate to drug sensitiv-
ity and could be used as predictive factors for a patient’s treatment
response.
Most of the studies to date have focused on mechanisms of
crosstalk between Notch and the PI3K pathway. Specifically, Ma
et al. showed that hyperactive mTOR signaling correlates with
increased Notch signaling in poorly differentiated breast cancers
and is also associated with a poor clinical outcome in women with
mTOR/Notch over expressing tumors (113). A variety of cancer
cell lines, including ER+MCF7 and triple negative MDA-MB-486
expresses elevated mTOR signaling and Notch activity. These cells
were used to ascertain the correlation between the two hyperac-
tive pathways. Ma et al. examined this correlation to find that RTK
activation of the PI3K/mTORC1 pathway caused up-regulation of
several new mTORC1 effectors: Signal Transducer and Activator
of Transcription 3 (STAT3), p63 (a member of the p53 family),
Jagged-1, Notch, and HES-1. Aberrant RTK/PI3K/AKT/mTORC1
signaling caused an increase in STAT3, which in turn increased p63
transcription. Elevated p63 increased Jagged-1-mediated Notch
activation and thus HES1 expression. This study presents the
mechanism by which the RTK/PI3K/AKT/mTOR pathway up-
regulates the STAT3/p63/Jag-1/Notch signaling cascade to induce
tumorigenesis. It has been reported that Notch is a positive reg-
ulator of the PI3K/AKT/mTOR pathway in T-ALL (106, 107)
suggesting that mTOR and Notch may cooperate in a shared regu-
latory loop to influence cancer cell differentiation or proliferation
in a dose dependent manner.
In another study by Mungamuri et al., increased Notch-1
expression and activity in cancer cells was shown to promote cell
survival, proliferation, as well as chemo-resistance. Specifically,
the investigators elucidated crosstalk between the Notch and PI3K
pathway in several different cancer cell lines, including a chemore-
sistant breast cancer cell line (MCF7), with increased Notch-1
expression and signaling (96). Activated Notch-1 signaling was
found to inhibit p53 activation by blocking nuclear localization
as well as phosphorylation at Ser15, Ser20, and Ser392 residues.
Blocking mTOR signaling using rapamycin treatment was shown
to sensitize cancer cells to chemotherapy by preventing Notch-
1-mediated down-regulation of p53. Conversely, up-regulation
of the mTOR downstream target eukaryotic initiation factor 4E
(eIF4E) caused chemo-resistance as well as inhibition of p53-
mediated apoptosis. These findings also support the critical role
of the PI3K/mTOR pathway on Notch-1-mediated regulation of
apoptosis and drug resistance.
An intriguing mechanism of communication between the
Notch and MAPK pathways has been elucidated by Izrailit et al.
(114). Active Notch-1 expression in the TNBC cell line MDA-
MB-231 was found to use the MAPK/ERK pathway to facilitate
Jagged-1 up-regulation and subsequent Notch activation. The
TGFβ pathway has also been implicated in regulating Jagged-1
expression to promote bone metastasis in breast cancer (115).
Using high throughput screening, Izrailit et al. found that the
pseudokinase Tribble-3 (TRB3) regulates activation of both the
MAPK/ERK and TGFβ pathways. Knock down of TRB3 reduced
MDA-MB-231 cell proliferation while Jagged-1 over expression in
the TRB3 silenced cells rescued cell proliferation. Similar stud-
ies were done in vivo in which the MDA-MB-231 cells with
TRB3 knock down had significantly smaller tumors than mice
with without TRB3 knock down. These results indicate that
TRB3 increases Jag-1 expression through the MAPK/ERK path-
way and this is critical to MDA-MB-231 cell proliferation and
tumorigenesis.
The studies in this review reveal communication between the
Notch and HER pathways in breast cancer cells that enable the
cell to compensate for the loss of one pathway with the potential
compensatory increase in the other. This research is continuing
to unveil multiple interactions between multiple pathways to dis-
cern the in depth complexity by which breast cancer cells are able
to thrive under a variety of targeted or cytotoxic cancer treat-
ments. Continued work in this area may shed light onto the
intricacies of pathway to pathway communication that could be
utilized in other forms of cancer and diseases. The Notch and
HER pathways have overlapping functions that justify their com-
pensatory relationship as both are able to promote cell survival,
growth, and motility, but nuances of either pathway may be able
to be teased out to further assess effects of compiling multiple
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targeted cancer treatments. For instance, the Notch pathway has
also been associated with increased angiogenesis via DLL4, IL-1,
or Leptin-mediated up-regulation of VEGF/VEGFR (116) as well
as AKT/mTOR-mediated up-regulation of glucose metabolism via
up-regulation of Glut 1 (117).
This review has summarized the communication mechanisms
between the Notch and HER receptors with a particular focus
on PI3K and MAPK signaling pathways. More studies are needed
to uncover novel interactions, downstream pathway mutations,
microRNA dysregulation, or epigenetic changes that may be criti-
cal to understanding how cancer cells move between pathways to
create their own signaling circuit for survival. Further assessment
of Notch–HER crosstalk in BCSC and stromal-cell communica-
tion could reveal differences in autocrine signaling to promote
BCSC growth and survival. Continuing to determine mechanisms
of action between critical oncogenic pathways such as Notch and
HER may enable scientists to better diagnose and treat breast and
other solid tumors using an increasingly specialized treatment plan
that may preemptively avoid development of treatment resistance,
CSC growth, and tumor recurrence.
CONCLUSION
Notch–HER crosstalk continues to yield insight into the com-
pensatory mechanisms used by breast and other cancer cells to
propagate cell survival, growth, metastasis, as well as drug resis-
tance. Combinatorial treatments targeting the HER and Notch
pathway simultaneously have yielded positive results in attempts
to combat acquired resistance to molecular targeted and cyto-
toxic therapies. The goal is ultimately, to prevent or reverse drug
resistance, as well as providing gene signatures that could preemp-
tively reveal potential resistance and sensitivity to combinatorial
treatment plans, in women diagnosed with HER+ or ER+ breast
cancer. Continued research will unravel mechanisms of Notch–
HER crosstalk to further improve clinical response to emerging
therapies as well as revitalize current therapies in hopes of contin-
ued improvement of treatment strategies for women with breast
cancer and other solid tumors.
Each breast cancer subtype is represented in Table 1 as well as
the molecular markers that each breast cancer subtype tends to
over express. The most common first and second line treatment
therapies for each subtype are included and it is important to note
that these therapies change based on the patient’s family history,
age, race, as well as tumor stage (invasiveness) and histological
grade. The rates of breast cancer subtype occurrence are approxi-
mated in this table (1). Advances in genomic driven classification
of breast cancer continue to evolve the subtypes, particularly in
TNBC, which can be further divided into: basal-like 1, basal-like 2,
immunomodulatory, mesenchymal-like, mesenchymal stem-like,
and luminal androgen receptor (12). Typical treatment options
are neoadjuvant, or adjuvant, meaning they include variations of
chemotherapy and/or radiotherapy before or after surgery, respec-
tively, in an effort to remove/eradicate as many tumor/cancer cells
as possible.
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